Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Purchase individual online access for 1 year to this journal.
Price: EUR 135.00Impact Factor 2024: 2.2
Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion.
The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.
Authors: Ghanjati, Foued | Beermann, Agnes | Hermanns, Thomas | Poyet, Cedric | Araúzo-Bravo, Marcos J. | Seifert, Hans-Helge | Schmidtpeter, Martin | Goering, Wolfgang | Sorg, Rüdiger | Wernet, Peter | Santourlidis, Simeon
Article Type: Research Article
Abstract: Urinary DNA is increasingly gaining importance in diagnosis of urological malignancies. Especially cell-free DNA originating from apoptotic and necrotic cells of the early tumor could become a key target for early stage tumor diagnosis. Aberrant DNA methylation forms tumor cell characteristic epigenetic profiles which are covalently established before any tumor related aberration at transcriptional or protein level has occurred. In addition, these epigenetic signatures are alterably adapted to and accompanying the individual stages of multistep, progressive tumorigenesis. Hence, they seem very promising for diagnosis as well as for monitoring the patient's follow-up care and even for decisions regarding personalized therapeutic …options. The essential prerequisite at this approach will be a reliable methodological handling of the biological material of interest. In this study we present detailed analyses of LINE-1 DNA methylation profiles and demonstrate the sensitive detection of LINE-1 DNA methylation differences as well as between cancer patients and healthy individuals, between urinary cellular and cell-free DNA. In addition, we show methylome differences between both DNA fractions from a healthy individual and bladder cancer patients. In conclusion, we demonstrate here the unrestricted amenability of urinary cell-free DNA for both, a detailed characterization of a distinct DNA methylation alteration and its sensitive detection and a comprehensive global, array-based screening for DNA methylation differences. Show more
Keywords: Cell-free DNA, DNA methylation, urine, diagnosis, bladder cancer
DOI: 10.3233/CBM-140407
Citation: Cancer Biomarkers, vol. 14, no. 5, pp. 295-302, 2014
Authors: Azab, Basem | Mohammad, Farhan | Shah, Neeraj | Vonfrolio, Steven | Lu, William | Kedia, Shiksha | Bloom, Scott W.
Article Type: Research Article
Abstract: Background: The neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) have been well studied as inflammatory markers and predictors for outcomes in colorectal cancer patients. Our aim was to determine the predictive value of both above ratios in colorectal cancer patients. Methods: This is a longitudinal retrospective study of a prospectively maintained database, included 580 patients, who had a complete blood count recorded before treatment (surgery or chemotherapy). We excluded patients presented with obstruction, infection, active hematological disease or those receiving steroid. The primary outcome (4-year cancer-related mortality) was obtained from our cancer registry. Results: …The 4-year cancer-related mortality rate in the 3rd tertile of NLR was 37% in comparison with 13% and 19% in lower tertiles, P value < 0.001. Similarly the 3rd tertile of PLR was 32% with 18% and 19% in lower tertiles, P value < 0.0005. In the multivariate survival analyses, elevated NLR was associated with higher mortality (a hazard ratio of 2.31(1.4–3.8) for the highest tertile and 5% increase in mortality for each unit increase in NLR, p < 0.001). Similarly, elevated NLR was a significant predictor for a worse disease-free survival. However, PLR was not significant predictor of mortality when adjusted for other confounding variables. Conclusion: Elevated pretreatment NLR is an independent predictor of both worse overall and disease free survival in colorectal cancer, whereas PLR was not after adjusting for confounding variables. Show more
Keywords: Colorectal cancer, survival, inflammation, neutrophil/lymphocyte, platelets/lymphocyte, NLR, PLR
DOI: 10.3233/CBM-140416
Citation: Cancer Biomarkers, vol. 14, no. 5, pp. 303-312, 2014
Authors: Tang, Hui | Mirshahidi, Saied | Senthil, Maheswari | Kazanjian, Kevork | Chen, Chien-Shing | Zhang, Kangling
Article Type: Research Article
Abstract: Background and Objective: Deficiency of vitamin D could be a major cause of colon cancer as suggested as early as 1980 by Drs. Cedric and Frank Garland of the University of California and has recently been underscored by a large European case control study. Whether vitamin D deficiency is because of inadequate intake (food and sunshine) or because of vitamin D metabolism disorder in the patient body is unknown. A proteomics approach to identify protein pathways associated with vitamin D transportation and metabolism pathways will help us understand better the pathology of the colon cancer. Methods: Lysates of …colon adenocarcinoma tissues and their matched healthy tissues, from seven colon cancer patients, have been evaluated by quantitative proteomics and bioinformatics analysis to determine protein expression profiles. Unsupervised hierarchical clustering and principle component analysis (PCA) were utilized for protein expression profiling and biomarker identification, while the reporter ion ratios from tandem-mass-tagging (TMT) labeled peptides were used for quantification. Ingenuity Pathway Analysis (IPA) was used to analyze protein pathways. Results and Conclusion: Proteomics analyses demonstrated that the proteins involved in vitamin D/E binding, heme/iron binding and transportation, and lipid/steroid transportation/metabolic systems were down-regulated in colon cancer and the same set of proteins were down-regulated in the LXR/RXR activation and acute-phase response pathways, revealing a plausible mechanistic connection between vitamin D deficiency, iron homeostasis, and colon cancer. Show more
Keywords: Colorectal cancer, vitamin D, LXR/RXR, tandem-masstagging, mass spectrometry
DOI: 10.3233/CBM-140409
Citation: Cancer Biomarkers, vol. 14, no. 5, pp. 313-324, 2014
Authors: Yu, Li-Jun | Li, Yan | Li, Cong | Li, Hong | Wu, Mo-Li | Liu, Zhi-Li | Kong, Qing-You | Chen, Xiao-Yan | Liu, Xiao-Yu | An, Li-Jia | Liu, Jia
Article Type: Research Article
Abstract: Background: S100A4 promotes cancer metastasis but is frequently silenced in human cutaneous squamous cell carcinomas/c-SCCs due to DNA methylation, which may explain the less metastasized property of c-SCCs. Objective: This study aims to check 1) whether the metastatic potential of S100A4-negative human c-SCC cells could be enhanced when S100A4 expression is restored in COLO16 c-SCC cells with S100A4 methylation and 2) the correlation of S100A4 expression and the differentiation grades and invasiveness of human c-SCC tumors. Methods: The motility and invasion of parent and transfected COLO16 cells are examined by the use of 24-well modified Boyden …chambers, scratched wound healing assay and nude mouse transplantation tumor model. Meanwhile, the correlation of S100A4 expression with growth patterns and grade of differentiation of c-SCC surgical specimens are analyzed. Results: S100A4 expression is successfully restored in COLO16 cells after plasmid lipofectamine transfection. Transwell and scratched wound healing assays shows that the invasion and migration activities of S100A4-expressing transfectants are higher than that of parent COLO16 cells. Subcutaneous and foot pad c-SCC models are established by injecting 5 × 10 6 / 100 l parental and S100A4-expressing COLO16 cells to BALB/c-nu/nude mice, respectively. Histological examination confirms the differences of invasiveness between the parent cells and the transfectants. Regional lymph node metastases are found only in the mice bearing S100A4-expressing tumors. S100A4 expression levels and frequencies are significantly different (P< 0.001) between the well and the poorly differentiated c-SCCs and closely correlated with tumor invasion (P< 0.05). Conclusions: S100A4 confers invasive and metastatic potentials on human c-SCCs. The low incidence of metastasis of c-SCCs, especially the well differentiated ones, might be due to the infrequent S100A4 expression. S100A4 can be regarded as a negative prognostic biomarker or a metastasis-risk factor of human c-SCCs. Show more
Keywords: S100A4, cutaneous squamous cancer cells, invasion, metastasis, gene transfection
DOI: 10.3233/CBM-140414
Citation: Cancer Biomarkers, vol. 14, no. 5, pp. 325-333, 2014
Authors: Nie, Fang | Zhao, Shi-Yi | Song, Fei-Xue | Li, Pei-Wu
Article Type: Research Article
Abstract: Background: Rac1, the better characterized Rac subfamily member, can regulate a large variety of different functions, including the organization of the actin cytoskeleton, cell migration, cell cycle progression, and cell survival through engagement of specific effectors. However, very little is currently known about the expression of Rac1 in colorectal cancer cells and the roles of Rac1 in the cell cycle progression and cell survival of human colorectal cancer cells. Objective: To assess the change of cytoskeleton and cell cycle in Lovo (human colorectal cancer) cell via deletion of Rac1 with RNA interference. Methods: Rac1 protein of …all selected human colorectal cancer cells and in human colorectal tissue was detected by Western blotting, Rac1-shRNA was used to silence the Rac1 to reduce its expression specifically in Lovo cells. Results: Rac1 protein was overexpressed in human colorectal cancer cells and in human colorectal tissue, RNA interference-mediated deletion of Rac1 strongly prolonged cell cycle progression and enhanced cell apoptosis of Lovo cells in vitro. Conclusions: depletion of Rac1 by the use of RNAi can arrest Lovo Cells in G0 /G1 and induce LoVo cells apoptosis. Show more
Keywords: Rac1, RNA interference, Cytoskeleton, cell cycle, cell apoptosis
DOI: 10.3233/CBM-140408
Citation: Cancer Biomarkers, vol. 14, no. 5, pp. 335-342, 2014
Authors: Eskandari-Nasab, Ebrahim | Hashemi, Mohammad | Ebrahimi, Mahboubeh | Amininia, Shadi | Bahari, Gholamreza | Mashhadi, Mohammad-Ali | Taheri, Mohsen
Article Type: Research Article
Abstract: Background: Recent evidence has demonstrated the implication of CC chemokine ligand 5 (CCL5) and CC chemokine receptor 5 (CCR5) in breast tumor initiation and progression. Objective: The purpose of this study was to investigate whether single nucleotide polymorphisms of CCL5 -403 G>A (rs2107538) and CCR5 Δ32 genes are associated with the breast cancer (BC) risk. Methods: A total of 439 subjects including on 236 BC patients and 203 healthy controls from the same area were recruited. The CCL5 -403 G>A and CCR5 Δ32 polymorphisms were genotyped by allele-specific polymerase chain reaction (AS-PCR) and PCR, respectively. …Results: Our data demonstrated that the CCL5 -403 GA and GA+AA genotypes, with a higher frequency in the BC patients compared to the control group, were associated with an increased risk of BC in the codominant (GG vs. GA OR=1.75, 95%CI=1.07–2.86, P=0.025) and dominant models (GG vs. GA+AA: OR=1.84, 95%CI=1.15–2.93, P=0.014), respectively. Additionally, the A allele of CCL5 -403 G>A variation was found more prevalent in the BC patients than in controls (14% vs. 8%) and was a risk factor for BC (G vs. A: OR=1.87, 95% CI=1.21–2.89, P=0.004). Conclusions: Our findings highlighted that the CCL5 -403 G>A polymorphism is a risk factor for BC in our population. Our findings suggest that the CCL5 -403 GA and GA+AA genotypes and the A allele were associated with an elevated risk of BC which may function as risk factor for breast carcinoma. Show more
Keywords: CCL5, CCR5, breast cancer, gene polymorphism
DOI: 10.3233/CBM-140411
Citation: Cancer Biomarkers, vol. 14, no. 5, pp. 343-351, 2014
Authors: Zhang, Yun | Liu, Lili | Li, Cui | Ai, Hao
Article Type: Research Article
Abstract: Background: The expressions of leptin and its receptor (ObR) have been observed in human endometrial cancer (EC) cells, and leptin can promote the proliferation of EC cells. However, the correlation between leptin and ObR expressions in EC and the clinicopathology of EC is still unclear. Objective: This study investigated the correlation between the expressions of leptin and ObR in EC and the clinicopathology of EC. Methods: Immunohistochemistry was used in this study. The correlation between the expressions of leptin and ObR in EC and the clinicopathology of EC was analyzed. Results: In the EC …specimens, the expressions of leptin and ObR were positively correlated with the invasiveness of the cancer and the obesity of patients, but inversely correlated with histological grade. The percentages of leptin and ObR were significantly higher in the patients with lymph node metastasis. Positive expression of leptin and ObR was associated with poorer prognosis (3-year survival rate). Moreover, the expression of leptin and ObR was associated with positive expression of estrogen receptor. Conclusions: Leptin and ObR are overexpressed in EC, and their expressions are associated with malignancy, invasion, and metastasis of EC. Thus, leptin and ObR may be important indicators in EC. Show more
Keywords: Endometrial cancer, leptin, ObR, clinicopathology
DOI: 10.3233/CBM-140415
Citation: Cancer Biomarkers, vol. 14, no. 5, pp. 353-359, 2014
Authors: Abols, A. | Ducena, K. | Zayakin, P. | Silina, K. | Kalnina, Z. | Sadovska, L. | Tars, J. | Vilmanis, J. | Narbuts, Z. | Eglitis, J. | Pirags, V. | Line, A.
Article Type: Research Article
Abstract: Background: Autoantibodies against tumor-associated antigens (TAAs) have been shown to serve as highly specific serological biomarkers for the diagnosis of various solid cancers. Although the autoimmunity against thyroid tissue specific antigens has been studied extensively, so far, the autoantibody responses against common TAAs such as cancer-testis antigens (CTAs), mutated or differentiation antigens have not been comprehensively analyzed in patients with thyroid cancer. Objective: The current study aims to characterize the frequency of autoantibody responses against common TAAs in patients with thyroid cancer and benign thyroid nodules. Methods: A phage-displayed antigen microarray comprising 65 TAAs was produced …and tested with sera from 53 patients with thyroid cancer, 90 patients with benign thyroid nodules and 96 cancer-free individuals, 100 melanoma, 54 breast cancer and 14 lung cancer patients as controls. Results: A panel of 6 TAAs was identified that preferentially reacted with sera from patients with thyroid cancer. The top ranked antigen in this panel was GAGE1 eliciting autoantibody response in 6% of patients with thyroid cancer but not with benign nodules, whereas no reactivity to other CTAs was detected in the sera from patients with thyroid cancer. Conclusions: Although six TAAs, including one CTA, showed thyroid cancer-associated reactivity, overall, spontaneous humoral immune responses against TAAs are rare in thyroid cancer and their utility for the development of non-invasive assay for the differential diagnosis of thyroid nodules is limited. Show more
Keywords: Phage-displayed antigen microarray, autoantibodies, thyroid nodules, thyroid cancer, cancer-testis antigens, biomarker
DOI: 10.3233/CBM-140413
Citation: Cancer Biomarkers, vol. 14, no. 5, pp. 361-369, 2014
Authors: Zou, Yingchang | Zhang, Xi | Chen, Xing | Hu, Yanjie | Ying, Kejing | Wang, Ping
Article Type: Research Article
Abstract: Background: Breath analysis became promising for noninvasive diagnosis of cancer with sophisticated spectrometry technology introduced. Objective: This study aimed to select volatile markers for lung cancer detection, which exclude the influences from non-malignant lung diseases. Methods: 171 subjects who were divided into three groups: patients with LC, patients with PNMD and healthy controls were enrolled in our studies as training cohort. The volatile organic compounds (VOCs) in their breath samples were analyzed with solid-phase micro-extraction/gas chromatography/mass spectrometry (SPME-GCMS). Markers were selected by receiver operating characteristic (ROC) curves. After that, 78 subjects with high morbidity of LC …were employed as validation cohort. Their breath samples were analyzed by thermal desorption instrument/gas chromatography/mass spectrometry (TD-GCMS). Results: Through a series of comparisons among lung cancer patients, pulmonary non-malignant diseases patients, and healthy participants in training cohort, Nonane,5-(2-methyl-)propyl-; phenol,2,6-di-tert-butyl-,4-methyl-; dodecane,2,6,11-trimethyl-; hexadecanal and pentadecane,8-hexyl- were selected as markers for lung cancer diagnosis. Principal component analysis was employ to process data from validation cohort. As results, satisfied distinctions have been obtained with detection of these five selected markers, although the detection method is not identical with that used for training cohort. Conclusions: In conclusion, with optimization method described in this paper, breath test could be an effective method for diagnosis of lung cancer and avoid the interference of pulmonary non-malignant diseases. Show more
Keywords: Lung cancer, volatile markers, breath test, pulmonary non-malignant disease
DOI: 10.3233/CBM-140418
Citation: Cancer Biomarkers, vol. 14, no. 5, pp. 371-379, 2014
Authors: Yu, Xinnian | Chen, Baoan | Cheng, Jian | Gao, Chong | Zhang, Xiaoping | Bao, Wen
Article Type: Research Article
Abstract: Objective: The Interleukin-10 (IL-10) gene polymorphism (–1082 A>G) has been linked to the risk of developing lymphoma, but the available results were inconsistent. To derive a more precise estimation, we performed a meta-analysis. Methods: A comprehensive search was conducted to examine all the eligible studies about IL-10-1082A>G polymorphism and lymphoma risk. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the association. Results: We included 12 studies, including 5847 cases and 6016 controls. The overall results suggested that the IL-10-1082G allele was associated with a borderline significantly increased risk of …lymphoma (G vs. A: OR=1.07, 95% CI=1.01–1.12; GG vs. AA: OR=1.14, 95% CI=1.02–1.26; and AG+GG vs. AA: OR=1.10, 95% CI=1.02–1.19). Stratifying by ethnicity (Caucasian and mixed), tumor type [non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL)], sample size (> 1000 and ≤ 1000 subjects) and Hardy-Weinberg equilibrium (HWE) in controls, similar results were found in mixed subgroup, NHL subgroup, large studies and the subgroup conforming to HWE. Conclusions: In conclusion, the meta-analysis suggests that the IL-10-1082A>G polymorphism is weakly associated with altered susceptibility to lymphoma. Further studies with haplotype analysis and on larger population of mixed ethnicity are warranted for a more definitive conclusion. Show more
Keywords: Lymphoma, meta-analysis, interleukin-10, polymorphism, susceptibility
DOI: 10.3233/CBM-140406
Citation: Cancer Biomarkers, vol. 14, no. 5, pp. 381-388, 2014
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]